Medical devices, healthcare technology and the business of care
PMA approval · P810031

HEALON, HEALON GV, HEALON5 PRODUCTS SODIUM HYALURONATE OPHTHALMIC VISCOELASTIC DEVICES

Johnson & Johnson Surgical Vision, Inc. · Decision date Jan 14, 1983

FDA DECISIONP810031

What did the FDA approve?

FDA records P810031 as an original PMA application. The recorded decision is approval, dated Jan 14, 1983.

An approval order statement is not included in the imported record. Open the FDA listing for the decision documents.

Regulatory pathway
Original PMA
Clinical specialty
Ophthalmic
Decision date
Jan 14, 1983

FDA source record

Regulatory record facts

Identifier
P810031
Regulatory pathway
Premarket approval application
Product code
LZP
Decision code
APPR
Decision date
Jan 14, 1983
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: AID, SURGICAL, VISCOELASTIC.

Product code
LZP
FDA device class
3

FDA decision timeline

  1. P810031 received

    Application receipt date recorded by FDA.

  2. P810031 · FDA decision

    APPR

  3. P810031/S083 · Related supplement

    Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD); Healon Duet PRO II Dual Pack Sodium Hya

Timeline entries are records held by MedtechLedger for P810031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P810031

Explore the linked device profile

Other records with product code LZP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Johnson & Johnson Surgical Vision, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
31 Technology Dr., Suite 200, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records